← Back to Search

Monoclonal Antibodies

XmAb20717 for Rare Cancers

Phase 2

Recruiting

Led By Arvind adasari@mdanderson.org, MD

Research Sponsored by M.D. Anderson Cancer Center

Eligibility Criteria Checklist

Specific guidelines that determine who can or cannot participate in a clinical trial

Must have

Cervical Cancer: Has recurrent, metastatic, or persistent cervical cancer and has received at least one prior line of systemic therapy and not amenable to curative treatment

Is of age ≥ 18

Timeline

Screening 3 weeks

Treatment Varies

Follow Up through study completion, an average of 1 year

Awards & highlights

Study Summary

This trial will test a new antibody to see if it is safe and effective for people with advanced rare cancers.

Who is the study for?

Adults with advanced rare cancers like mesothelioma, lung cancer, neuroendocrine carcinoma, cervical cancer, and Hodgkin's lymphoma. Participants must have measurable disease by specific criteria, be in good physical condition (ECOG 0-1), use effective birth control if applicable, and meet certain lab test requirements. Exclusions include recent treatment for the studied cancer or other therapies, severe allergies to study drug components, untreated brain metastases among others.Check my eligibility

What is being tested?

The trial is testing XmAb20717's safety and effectiveness on patients with various advanced rare cancers. It aims to see how well this intervention works across different types of these diseases under a unified protocol.See study design

What are the potential side effects?

While not explicitly listed here, side effects may include typical reactions associated with immunotherapy such as fatigue, skin reactions, digestive issues; immune-related conditions affecting organs; infusion-related symptoms; and potential increased risk of infections.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below

Select...

My cervical cancer has returned, spread, or persists despite treatment and cannot be cured.

Select...

I am 18 years old or older.

Select...

I am fully active or can carry out light work.

Select...

My cancer is MSI-H and I haven't had specific immune therapies.

Select...

My advanced peritoneal mesothelioma didn't respond to or couldn't tolerate the standard chemotherapy, or I haven't been treated but can't receive it.

Select...

My blood and organ tests meet the required health standards.

Select...

I have extensive-stage small-cell lung cancer and was treated with platinum-based therapy.

Select...

I have a high-grade neuroendocrine carcinoma outside the lungs and was treated with platinum-based chemotherapy.

Select...

My Hodgkin lymphoma has returned or didn't respond to first-line chemotherapy.

Timeline

Screening ~ 3 weeks3 visits

Treatment ~ Varies

Follow Up ~ through study completion, an average of 1 year

Screening ~ 3 weeks

Treatment ~ Varies

Follow Up ~through study completion, an average of 1 year

This trial's timeline: 3 weeks for screening, Varies for treatment, and through study completion, an average of 1 year for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.

Primary outcome measures

To establish the efficacy of XmAb20717 as measured by overall response rate.

Trial Design

1Treatment groups

Experimental Treatment

Group I: XmAb20717Experimental Treatment1 Intervention

Participants will receive XmAb20717 by vein over 1 hour on Days 1 and 15 of each cycle.

Treatment

First Studied

Drug Approval Stage

How many patients have taken this drug

XmAb20717

2018

Completed Phase 1

~150

0 / 9Eligibility criteria met

Find a Location

Who is running the clinical trial?

M.D. Anderson Cancer CenterLead Sponsor

2,980 Previous Clinical Trials

1,789,710 Total Patients Enrolled

Arvind adasari@mdanderson.org, MDPrincipal InvestigatorM.D. Anderson Cancer Center

Arvind Nageshwara Dasaru, MDPrincipal InvestigatorM.D. Anderson Cancer Center

Media Library

XmAb20717 (Monoclonal Antibodies) Clinical Trial Eligibility Overview. Trial Name: NCT05337735 — Phase 2

Cancer Clinical Trial 2023: XmAb20717 Highlights & Side Effects. Trial Name: NCT05337735 — Phase 2

XmAb20717 (Monoclonal Antibodies) 2023 Treatment Timeline for Medical Study. Trial Name: NCT05337735 — Phase 2

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Is the administration of XmAb20717 associated with any significant risks?

"XmAb20717 safety metrics were graded a 2, since there is only limited evidence backing its efficacy but substantial data demonstrating it's safe for human use."

Answered by AI

Are any openings left for this experiment?

"Affirmative, the information available on clinicaltrials.gov confirms that this medical trial is open to recruitment. This study was first made public on August 5th 2022 and has since been updated as recently as September 14th 2022 . The research team requires 140 participants from one particular clinic site."

Answered by AI

What is the current size of the cohort undergoing this experimental treatment?

"Correct. According to the records on clinicaltrials.gov, recruitment has been active since August 5th 2022 and is still going strong as of September 14th 2022 with a goal of admitting 140 participants into one location."

Answered by AI

Recent research and studies

clinicaltrials.govStudy

A Phase II Clinical Trial to Evaluate Safety and Efficacy of XmAb20717 in Advanced Rare Cancers

2022. "A Phase II Clinical Trial to Evaluate Safety and Efficacy of XmAb20717 in Advanced Rare Cancers". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT05337735.

All > Mesothelioma